Indications
Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Composition
- Active substance
- efbemalenograstim alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ryzneuta
- Active substance
- efbemalenograstim alfa
- ATC code
- L03AA18
- Marketing authorisation holder
- Evive Biotechnology Ireland Limited
- Status
- Authorised